Valuation: Grace Therapeutics, Inc.

Market Cap 63.05M 45.44M 39.24M 36.88M 33.54M 4.34B 64.09M 432M 169M 2.18B 171M 167M 7.23B P/E 2027 *
-4.07x
P/E 2028 * -3.87x
Enterprise Value 63.05M 45.44M 39.24M 36.88M 33.54M 4.34B 64.09M 432M 169M 2.18B 171M 167M 7.23B EV / Sales 2027 *
-
EV / Sales 2028 * 8.05x
Free-Float
59.16%
Yield 2027 *
-
Yield 2028 * -
1 day+4.35%
1 week+1.41%
Current month+3.85%
1 month-10.37%
6 months-40.17%
Current year-37.57%
1 week 2.02
Extreme 2.02
2.19
1 month 1.85
Extreme 1.85
2.48
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
23.13
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 2023-04-03
Director of Finance/CFO 55 2024-01-04
Chief Tech/Sci/R&D Officer 65 2023-05-07
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 2023-04-03
Director/Board Member 59 2023-10-09
Date Insider Type Main position Quantity % Market Cap.
1/12/26 Option

Chairman

10,000 0.0646%
1/12/26 Option

Director

10,000 0.0646%
1/12/26 Option

Director

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+1.41%-33.74%+0.47% 45.44M
-1.90%+2.85%+62.82%+104.39% 70.07B
-3.21%-4.32%+31.85%+58.98% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
+1.11%-0.74%+47.68%+10.98% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+0.10%+1.40%+35.36%-19.47% 18.75B
-1.15%-2.84%+14.93%+555.81% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +0.35%+1.89%+43.78%+176.49% 26.37B
Weighted average by Cap. -0.87%+0.55%+50.08%+159.35%

Financials

2027 *2028 *
Net sales - 7.83M 5.64M 4.88M 4.58M 4.17M 540M 7.96M 53.68M 20.99M 270M 21.19M 20.73M 898M
Net income -12.76M -9.19M -7.94M -7.46M -6.79M -879M -12.97M -87.43M -34.19M -440M -34.52M -33.77M -1.46B -20.46M -14.75M -12.74M -11.97M -10.88M -1.41B -20.8M -140M -54.83M -706M -55.37M -54.16M -2.35B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
26-08-14 US$2.160 +4.35% 397,808
26-08-13 US$2.070 -1.43% 193,827
26-08-12 US$2.100 -0.94% 121,836
26-08-11 US$2.120 +0.47% 97,764
26-08-10 US$2.110 -0.94% 184,322
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.997CAD
Average target price
8.404CAD
Spread / Average Target
+180.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock